trending Market Intelligence /marketintelligence/en/news-insights/trending/O1JmLybAVXKJP_jktxd5JQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Elpiscience Biopharmaceuticals secures $100M in series B round

COVID-19’s Impact on the Capital Markets: Identifier Issuance for Municipal Securities Sinks, but Corporate Requests Stable

How 37 Years of Default Data Can Prepare Us for the COVID-19 Fallout

How 37 Years of Default Data Can Prepare Us for the COVID-19 Fallout

IoT and AI Aid Critical Event Management to Battle COVID-19, but Deployment could Raise Privacy Concerns


Elpiscience Biopharmaceuticals secures $100M in series B round

Chinese biopharmaceutical research and development company Elpiscience Biopharmaceuticals Co. Ltd. raised $100 million in a series B funding round led by Hyfinity Investments.

Tencent, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont and Parkway Global are among those who participated in the round, including current investors such as Lilly Asia Ventures, Hillhouse Capital Group and CDH Investments.

The cancer immunotherapy-focused company will mainly use the capital to advance immunotherapy candidates through pre-clinical and clinical development, as well as to broaden its product pipeline.

Elpiscience Biopharmaceuticals also entered into a partnership with Bank of China and Agricultural Bank of China for a 150 million Chinese yuan fund that will be used to build its good manufacturing practice capabilities.

As of Dec. 27, US$1 was equivalent to 7.00 Chinese yuan.